[177Lu-DOTA0,Tyr3]-octreotate in the treatment of midgut neuroendocrine tumors
نویسندگان
چکیده
منابع مشابه
Neoadjuvant Treatment of Nonfunctioning Pancreatic Neuroendocrine Tumors with [177Lu-DOTA0,Tyr3]Octreotate.
UNLABELLED Pancreatic neuroendocrine tumors (NETs) are rare neoplasms for which surgery has almost the only potential for cure. When surgery is not possible because of tumor size and vascular involvement, neoadjuvant treatment with [(177)Lu-DOTA(0),Tyr(3)]octreotate ((177)Lu-octreotate) may be an option. METHODS We studied 29 Dutch patients with a pathology-proven nonfunctioning pancreatic NE...
متن کاملLong-Term Efficacy, Survival, and Safety of [177Lu-DOTA0,Tyr3]octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine Tumors.
Purpose: Bronchial and gastroenteropancreatic neuroendocrine tumors (NET) are slow-growing tumors, which frequently express somatostatin receptors on their cell membranes. These receptors are targets for therapy with Lutetium-177-labeled somatostatin analogues. We have treated over 1,200 patients with peptide receptor radionuclide therapy (PRRT) with [177Lu-DOTA0,Tyr3]octreotate (177Lu-DOTATATE...
متن کاملQuality of life in 265 patients with gastroenteropancreatic or bronchial neuroendocrine tumors treated with [177Lu-DOTA0,Tyr3]octreotate.
UNLABELLED Quality of life (QOL) is an important outcome in cancer therapy. In this study, we investigated the QOL and symptoms after [(177)Lu-DOTA(0),Tyr(3)]octreotate ((177)Lu-octreotate) therapy in patients with inoperable or metastasized gastroenteropancreatic or bronchial neuroendocrine tumors (NETs). METHODS Two hundred sixty-five Dutch patients completed the QOL questionnaire of the Eu...
متن کاملNAMPT Inhibitor GMX1778 Enhances the Efficacy of 177Lu-DOTATATE Treatment of Neuroendocrine Tumors.
Neuroendocrine tumors (NETs) can be treated by peptide receptor radionuclide therapy using radiolabeled somatostatin analogs. However, the efficacy of such treatment is low and needs to be optimized. Our study evaluated the potential radiosensitizing effects of inhibition of nicotineamide phosphoribosyltransferase on 177Lu-DOTATATE treatment in a NET model. METHODS Nude mice xenografted with ...
متن کامل1165TiPNETTER-1: FIRST PIVOTAL PHASE III STUDY EVALUATING 177LU-DOTATATE IN MIDGUT NEUROENDOCRINE TUMOURS.
1165TiP Citation: Annals of Oncology, Volume 25, Supplement 4, 2014 NETTER-1: FIRST PIVOTAL PHASE III STUDY EVALUATING 177LU-DOTATATE IN MIDGUT NEUROENDOCRINE TUMOURS M. Lopera Sierra, D. Kwekkeboom, M.F. Mariani, L. Bodei, P. Santoro, E.P. Krenning 1 Medical Affaires, Advanced Accelerator Applications, Saint Genis Pouilly, FRANCE 2 Nuclear Medicine, Erasmus University Medical Center, Rotterdam...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Future Oncology
سال: 2016
ISSN: 1479-6694,1744-8301
DOI: 10.2217/fon.15.321